Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ireland based medical diagnostics company Trinity Biotech has introduced its GeneSys platform for infant hemoglobinopathies.
Subscribe to our email newsletter
The GeneSys system is claimed to be the first on the market to offer a fully automated approach for newborn screening while providing positive identification for all major infant hemoglobin variants. The system also offers the unique time saving capability of allowing laboratories to run a confirmatory test on the same instrument for all positive results.
Trinity will market the GeneSys system to the 38 US state laboratories that participate in the national neonatal screening program immediately upon its release.
Brendan Farrell, CEO of Trinity Biotech, said: “The Trinity GeneSys platform provides a number of competitive advantages to the alternative products currently used by US state laboratories. It provides screening results in two minutes and it enables confirmatory tests to be run on the same instrument.”